|
|---|
Category:Letter
MONTHYEARML24012A1422024-01-31031 January 2024
Exemption from Select Requirements of 10 CFR Part 73 (EPID L-2023-LLE-0051 (Security Notifications, Reports, and Recordkeeping and Suspicious Activity Reporting))
IR 05000416/20230042024-01-25025 January 2024
Integrated Inspection Report 5000416/2023004
ML24018A0222024-01-18018 January 2024
Core Operating Limits Report (COLR) Cycle 24, Revision 2
IR 05000416/20243012024-01-16016 January 2024
NRC Initial Operator Licensing Examination Approval 05000416/2024301
ML24012A1962024-01-12012 January 2024
Response to 2nd Round Request for Additional Information Concerning Relief Request Number EN-RR-22-001 Proposed Alternative to Use ASME Code Case N-752, Risk-Informed Categorization and
ML23349A1672023-12-21021 December 2023
Request for Withholding Information from Public Disclosure
ML23348A3572023-12-14014 December 2023
Application to Revise Technical Specifications to Use Online Monitoring Methodology Slides and Affidavit for Pre-Submittal Meeting
ML23348A3712023-12-14014 December 2023
Notification of an NRC Fire Protection Baseline Inspection (NRC Inspection Report (05000416/2024011) and Request for Information
ML23340A2222023-12-13013 December 2023
Project Manager Assignment
ML23352A0292023-12-13013 December 2023
Entergy - 2024 Nuclear Energy Liability Evidence of Financial Protection
ML23340A1592023-12-13013 December 2023
Entergy Operations, Inc. - Entergy Fleet Project Manager Assignment
ML23333A1362023-11-29029 November 2023
Supplement to Request for Exemption from Enhanced Weapons, Firearms Background Checks, and Security Event Notifications Implementation
ML23325A1422023-11-21021 November 2023
Request for Exemption from Enhanced Weapons, Firearms Background Checks, and Security Event Notifications Implementation
IR 05000416/20234032023-11-13013 November 2023
Security Baseline Inspection Report 05000416/2023403 Cover Letter
ML23311A2082023-11-0909 November 2023
Reassignment of U.S. Nuclear Regulatory Commission Branch Chief in the Division of Operating Reactor Licensing for Plant Licensing Branch IV
IR 05000416/20230032023-11-0808 November 2023
Integrated Inspection Report 05000416/2023003
ML23270B9932023-09-29029 September 2023
Request to Update ASME Boiler & Pressure Vessel Code Relief Request SE with NRC-Approved Revision of Bwrip Guidelines (GG-ISI-020 & RBS-ISI-019) (EPID L-2022-LLR-0090) - Non-Proprietary
ML23270B1892023-09-27027 September 2023
Evacuation Time Estimate Study
ML23269A1242023-09-27027 September 2023
Request for Withholding Information from Public Disclosure
ML23240A3952023-08-28028 August 2023
Reply to a Notice of Violation; EA-23-019
IR 05000416/20230052023-08-21021 August 2023
Updated Inspection Plan for Grand Gulf Nuclear Station (Report 05000416/2023005)
ML23226A1002023-08-18018 August 2023
Regulatory Audit in Support of License Amendment Requests to Adopt TSTF-505, Revision 2, and 10 CFR 50.69
IR 05000416/20230022023-08-0808 August 2023
Integrated Inspection Report 05000416/2023002 and Independent Spent Fuel Storage Installation Inspection Report 07200050/2023001
IR 05000416/20234042023-08-0707 August 2023
Material Control and Accounting Program Inspection Report 05000416/2023404
IR 05000416/20230912023-07-28028 July 2023
Final Significance Determination of a Green Finding and Notice of Violation; NRC Inspection Report 05000416/2023091
ML23208A2112023-07-27027 July 2023
Entergy Operations Inc., Application to Revise Technical Specifications to Adopt TSTF-205, Revision of Channel Calibration, Channel Functional Test, and Related Definitions
ML23166B0712023-06-15015 June 2023
Reply to Notice of Violation EA-22-104 and EA-22-115
ML23166B0662023-06-15015 June 2023
Response to NRC Integrated Inspection Report 05000416/2023001
ML23159A2302023-06-0808 June 2023
Response to Request for Additional Information Concerning Request to Update ASME Code Relief Request Safety Evaluations with NRC-Approved Revision of BWRVIP Guidelines (GG-ISI-020, and RBS-ISI-019)
GNRO-2023/00014, License Amendment Request to Revise Technical Specifications to Adopt Risk Informed Completion Times TSTF-505, Revision 2, Provide Risk-Informed Extended Completion Times - RITSTF Initiative 4b2023-06-0606 June 2023
License Amendment Request to Revise Technical Specifications to Adopt Risk Informed Completion Times TSTF-505, Revision 2, Provide Risk-Informed Extended Completion Times - RITSTF Initiative 4b
GNRO-2023/00015, Application to Adopt 10 CFR 50.69, Risk-Informed Categorization and Treatment of Structures, Systems and Components for Nuclear Power Reactors2023-06-0606 June 2023
Application to Adopt 10 CFR 50.69, Risk-Informed Categorization and Treatment of Structures, Systems and Components for Nuclear Power Reactors
ML23122A1632023-05-18018 May 2023
NRC Inspection Report 05000416/2023090 and Preliminary White Finding
IR 05000416/20234022023-05-17017 May 2023
Security Baseline Inspection Report 05000416/2023402
ML23110A8002023-05-10010 May 2023
Notice of Violation; Integrated Inspection Report 05000416/2023001 and NRC Investigation Report 4-2022-004
ML23130A2732023-05-10010 May 2023
and Waterford 3 Steam Electric Station - Response to Regulatory Issue Summary 2023-01, Preparation and Scheduling of Operator Licensing Examinations
IR 05000416/20230012023-05-10010 May 2023
Notice of Violation; Integrated Inspection Report 05000416/2023001 and NRC Investigation Report 4-2022-004
ML23117A2172023-05-0101 May 2023
Safety Evaluation for Quality Assurance Program Manual Reduction in Commitment
ML23117A0422023-04-27027 April 2023
Annual Radioactive Effluent Release Report (ARERR)
ML23111A2132023-04-21021 April 2023
Responses to RAI Concerning Relief Request Number EN-RR-22-001 Proposed Alternative to Use ASME Code Case N-752, Risk-Informed Categorization and Treatment for Repair/ Replacement Activities
ML23110A1122023-04-20020 April 2023
Annual Report for Entergy Quality Assurance Program Manual Changes Under 10 CFR 50.54(a)(3), 10 CFR 71.106, and 10 CFR 72.140(d). Notification of Application of Approved Appendix B to 10 CFR 72 Subpart G
ML23110A0552023-04-20020 April 2023
Annual Radiological Environmental Operating Report (AREOR)
ML23103A1022023-04-13013 April 2023
Annual Report of Individual Monitoring - NRC Form 5 for 2022 Per 10 CFR 20.2206
ML23102A1482023-04-12012 April 2023
Notification of NRC Initial Operator Licensing Examination 05000416/2024301
ML23089A0602023-03-30030 March 2023
Entergy Operations, Inc. - Fleet Project Manager Assignment
ML23088A3922023-03-29029 March 2023
Nuclear Onsite Property Damage Insurance (10 CFR 50.54(w)(3))
ML23079A2772023-03-21021 March 2023
U.S. Nuclear Regulatory Commission Presentation at the May 1, 2023, Port Gibson City Council Meeting
ML23080A2882023-03-21021 March 2023
Decommissioning Funding Status Report Per 10 CFR 50.75(f)(1) Entergy Operations, Inc
IR 05000416/20230112023-03-0808 March 2023
Design Basis Assurance Inspection Report 05000416/2023011
2024-01-31
[Table view]
Category:License-Fitness for Duty (FFD) Performance Report
MONTHYEARML23059A0932023-02-28028 February 2023
Annual Fatigue Report Form for 2022
ML23058A3382023-02-27027 February 2023
Single Positive Test Form Collected on 05/03/2022
ML23058A3882023-02-27027 February 2023
Single Positive Test Form Collected on 10/26/2022
ML23058A3102023-02-27027 February 2023
Single Positive Test Form Collected on 02/22/2022
ML23058A3372023-02-27027 February 2023
Single Positive Test Form Collected on 04/06/2022
ML23058A2572023-02-27027 February 2023
Annual Report Form for Drug and Alcohol Tests for 2022
ML23058A3112023-02-27027 February 2023
Single Positive Test Form Collected on 02/14/2022
ML23058A3072023-02-27027 February 2023
Single Positive Test Form Collected on 01/18/2022
ML23058A3062023-02-27027 February 2023
Single Positive Test Form Collected on 02/08/2022
ML23058A3922023-02-27027 February 2023
Single Positive Test Form Collected on 02/27/2022
ML23058A3932023-02-27027 February 2023
Single Positive Test Form Collected on 02/07/2022
ML23058A3042023-02-27027 February 2023
Single Positive Test Form Collected on 01/10/2022
ML23058A3832023-02-27027 February 2023
Single Positive Test Form Collected on 07/18/2022
ML23058A3842023-02-27027 February 2023
Single Positive Test Form Collected on 08/04/2022
ML23058A3312023-02-27027 February 2023
Single Positive Test Form Collected on 03/29/2022
ML23058A3132023-02-27027 February 2023
Single Positive Test Form Collected on 02/14/2022
ML23058A3392023-02-27027 February 2023
Single Positive Test Form Collected on 05/23/2022
ML23058A3262023-02-27027 February 2023
Single Positive Test Form Collected on 02/24/2022
ML23058A3822023-02-27027 February 2023
Single Positive Test Form Collected on 07/15/2022
ML23058A3812023-02-27027 February 2023
Single Positive Test Form Collected on 07/13/2022
ML23058A3082023-02-27027 February 2023
Single Positive Test Form Collected on 02/22/2022
ML23058A3292023-02-27027 February 2023
Single Positive Test Form Collected on 03/29/2022
ML23058A3162023-02-27027 February 2023
Single Positive Test Form Collected on 03/31/2022
ML23058A3872023-02-27027 February 2023
Single Positive Test Form Collected on 10/29/2022
ML23058A3852023-02-27027 February 2023
Single Positive Test Form Collected on 07/25/2022
ML23058A3272023-02-27027 February 2023
Single Positive Test Form Collected on 03/29/2022
ML23058A3092023-02-27027 February 2023
Single Positive Test Form Collected on 02/24/2022
ML23058A3332023-02-27027 February 2023
Single Positive Test Form Collected on 03/30/2022
ML23058A3802023-02-27027 February 2023
Single Positive Test Form Collected on 06/14/2022
ML23058A3862023-02-27027 February 2023
Single Positive Test Form Collected on 09/15/2022
ML23058A3052023-02-27027 February 2023
Single Positive Test Form Collected on 02/09/2022
ML23058A3912023-02-27027 February 2023
Single Positive Test Form Collected on 10/26/2022
ML23058A3892023-02-27027 February 2023
Single Positive Test Form Collected on 11/08/2022
ML23058A3402023-02-27027 February 2023
Single Positive Test Form Collected on 06/02/2022
ML23058A3352023-02-27027 February 2023
Single Positive Test Form Collected on 03/30/2022
ML23058A3902023-02-27027 February 2023
Single Positive Test Form Collected on 10/26/2022
ML23058A3122023-02-27027 February 2023
Single Positive Test Form Collected on 02/14/2022
ML23047A4472023-02-16016 February 2023
Submittal of 30 Day Report Per 10 CFR 26.719(c) Blind Performance Testing
ML23058A3242023-02-10010 February 2023
Single Positive Test Form Collected on 3/17/2022
ML23058A3142023-02-10010 February 2023
Single Positive Test Form Collected on 3/11/2022
ML23058A3152023-02-10010 February 2023
Single Positive Test Form Collected on 3/13/2022
ML23058A3212023-02-10010 February 2023
Single Positive Test Form Collected on 3/03/2022
ML23058A3202023-02-10010 February 2023
Single Positive Test Form Collected on 3/08/2022
ML23058A3222023-02-10010 February 2023
Single Positive Test Form Collected on 3/15/2022
ML22056A4252022-02-25025 February 2022
Single Positive Test Form Collected on 10/27/2021
ML22056A4242022-02-25025 February 2022
Single Positive Test Form Collected on 09/22/2021
ML22056A4162022-02-25025 February 2022
Single Positive Test Form Collected on 07/21/2021
ML22056A4182022-02-25025 February 2022
Single Positive Test Form Collected on 09/13/2021
ML22056A4202022-02-25025 February 2022
Single Positive Test Form Collected on 09/20/2021
ML22056A4192022-02-25025 February 2022
Single Positive Test Form Collected on 07/08/2021
2023-02-28
[Table view] |
Text
entergy Entergy Operations, Inc.
P.O. Box 756 Port Gibson, Mississippi 39150 Jeffery A. Hardy Manager Regulatory Assurance Grand Gulf Nuclear Station Tel: 802-380-5124 10 CFR 26.719(c)
GNRO2023-00004 February 16, 2023 U.S. Nuclear Regulatory Commission Attn: Document Control Desk Washington, DC 20555-0001
SUBJECT:
Unsatisfactory Laboratory Testing Report Grand Gulf Nuclear Station, Unit 1 Docket No. 50-416 Renewed License No. NPF-29 In accordance with 10 CFR 26.719(c), Grand Gulf Nuclear Station, Unit 1 (Grand Gulf) is reporting unsatisfactory blind performance testing results from Quest Diagnostics, for the Grand Gulf Fitness for Duty Program (FFD).
An investigation was conducted pertaining to invalid blind performance testing results. The cause was determined to be chromatographic interference. contains the investigation report by Grand Gulf. Attachments 2 & 3 contain the investigation report and follow-up investigation report from Quest Diagnostics. Attachment 4 contains correspondence from EISohly Laboratories indicating the action taken to resolve the interference.
This letter contains no new Regulatory Commitments. Should you have any questions concerning the content of this letter, please contact me at 802-380-5124.
SincerOL ~ -
JAH/trj
Attachment:
- 1. Blind Sample Investigation Report
- 2. Quest Diagnostics Investigation Report
- 3. Quest Diagnostics Investigation Follow-up Report
- 4. Email from EISohly Laboratories, Incorporated (ELI)
G N RO2023-00004 Page 2 of 2 cc: NRC Senior Resident Inspector Grand Gulf Nuclear Station Port Gibson, MS 39150 U.S Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555-0001
G NRO2023-00004 Page 1 of 2 Attachment 1 Blind Sample Error Investigation Report Identification of Error Blind Specimen Identification Number (ID) 3590783 was purchased from EISohly Laboratories to meet requirements of sample testing for blind specimens. Blind performance samples were sent to Quest Diagnostics in Lenexa, Kansas in October 2021 for testing.
The laboratory, Quest Diagnostics, reported the results of one blind specimen, with accession number 815859D, as positive for codeine, morphine and invalid: Gas Chromatography-Mass Spectrometry (GC/MS) interference.
Investigation Specimen 3590783 was submitted to Quest Diagnostics on 10/14/2021 with predetermined value and positive for Opiates. Results were returned from Quest Diagnostics on 10/19/2021.
Investigation report was received from Quest Diagnostics on January 30, 2021.
The specimen reported as positive for Opiates as expected, but the 6-Acetylmorphine returned as Invalid results: GC/MS Interference.
Quest Diagnostics reported the specimen exhibited chromatographic interference on two different GC/MS confirmation procedures for 6-acetylmorphine (6-AM). The laboratory was unable to obtain acceptable ion-ratios for the specimen in both confirmation batches.
The specimen was analyzed using both their routine and alternative methods for 6-AM. The specimen was analyzed on both methods twice and failed to meet the ion-ratio criteria within plus or minus 20%.
The specimen was purchased from EISohly laborites. The specimen was received and immediately placed in refrigeration upon receipt. Preparation and shipment for this specimen was consistent with conventional preparation and shipment practices.
Follow-up report from Quest Diagnostics dated January 3, 2023, states that from November 2021 to November 2022 there was a total of 6 specimens that were reported as invalid, but none of them were invalid for 6-AM.
Email from EISohly Laboratories dated February 2, 2023, states that the issue was resolved by using a different blank urine matrix.
Cause Quest Diagnostics has been unable to identify the cause of the GC/MS interference. The interference exhibited by this blind is a known issue. The laboratory has been working with EISohly Laboratories to rectify the problem. Email from EISohly Laboratories dated February 2, 2023, states that the issue was resolved by using a different blank urine matrix.
GN RO2023-00004 Page 2 of 2 GGNS Actions
- 1. Notified Entergy Fleet Plants of the discrepancy
- 2. Notified the Manager, AA/FFD and the Medical Review Officer
- 3. Notified EISohly Laboratories and Quest Diagnostics - Lenexa of the discrepancy and requested an investigation/inquiry
- 4. No additional actions are required at this time.
GNRO2023-00004 Page 1 of 1 Attachment 2 Quest Diagnostics Investigation Report St@ven P. Cllamblfss, Supel"Yisor M/FFD/Medical Grand Gulf Nudear Statton RE: Spedi'Oi!!!n ID: 3590783 Aceiession No. 815859D
Dear Mr. Chamblfss:
Thhi letter Is In response to a communication rec~wd from your offrce on October 28, 2021, re,ardlrc the reporting of the abo\lll! rofetll!Oced specimen.
Peryoor request, we haw completed th@ tnveStigation fnto the analysis of the above rofll!'r<<ia!!cl specimen rdentified by you as a blind specfmen. The specimen w.is received at the laboratory October l, 2021, and reported as positive for codeiM, morphine and Invalid: GCMS lnterferenc@ on October 14, 2021.
The specimen exhibited chrom3'tographlc lnt<<ference on two different 11:S chromatogniiphy-mass spectrometry (GC-MS} confirmation procedurEis for 6-acetylmorphine (6-AM}. The laboratory was unable to obtafn ac:ceptable ion-ratios for the Sf:)eclmert In both ci:mfirmation batches.
The specimen w.u analyzed US!Tl@ both our routine and altttrnatlve methods for 6-acetylmorplllne. An alternative methQ<f is utiUzed In Instances wile<<! a sample exhibits chromatographic ioterference on the prim.;iry, routme method. Th,ls specfmen was analvzed on both m~(lds twice and failed to meet the laboratory's ideritification aiter"8 flon*ratlo within +/-20%} on both methods. On the first analysfs usr111 the rm.1tine and altemat:Tve methods1 the specimen guantmed at 18 nlfm L and 19 ng/ml., respectf\lely, with unacceptable ion-ratios. In an attempt to n!!solve the issue, the speeimen was n!ip@ated on diJYtlon on both methods. The quantitrnw rMults for thil!! diluted specimen using thie routine and il'ltem1tiw methods were 23 ng/ml and 24 ng{m l, Nspectively, with un,a,cceptaible ion ratios on both analyses. Since all quantitative testfoS of this spedm@n failed to ml!et identific:atkm crit@ria the sample was reported ai Indicated above Th4'? tnterfenmc:e ediibited by thb blrnd Is a known issue. The laborDtonJ Is working with EISohly Laboratories to r@ctffy the problem and h,ope to have It rMolwd In the near future, Ple3:Se a.II me at 91:3-577*1512 if you need any other Information or have questions, Shane Responsible Person / Lab Marnager
GNRO2023-00004 Page 1 of 1 Attachment 3 Quest Diagnostics Investigation Follow-up Report Quest Diagnostics"'
January 3, 2023 Steven P. Chambliss, Supervisor AA/FFD/Medical Grand Gutt Nuclear Station RE: Follow-up to Specimen ID: 3590783 Accession No: 815859D
Dear Mr. Chambliss:
This letter is a follow-up to a communication we sent to your office on December 9, 2021, regarding the reporting of the above referenced specimen and our corrective action.
In the original communication, the laboratory stated that the interference on the 6-acetylmorphine (6-AM) blind was a known issue and that the laboratory was working with EISohly Laboratories, manufacturer of the blind, to rectify the problem. The laboratory is not able to provide any details into what EISohly Laboratories did to resolve the issue. However, we did review your account to look for specimens that reported as Invalid from November 2021 through the end of November 2022. There was a total of 6 specimens that reported as Invalid, but none of them were Invalid for 6-AM. This leads the laboratory to believe that EISohly Laboratories has rectified the problem as seen with specimen ID 3590783.
Please call me at 913-577-1632 if you need any other information or have questions.
Sincerely, n~~
Dawn Hahn Laboratory Operation Director/Responsible Person
G N RO2023-00004 Page 1 of 1 Attachment 4 Email from EISohly laboratories, Incorporated (EU)
From: Denise Forsyth <dforsyth@elsohly.com>
Sent: Thursday, February 2, 2023 4:49 PM To: Ezell, Dennis <DEZELL@entergy.com>
Cc: Chambliss, Steven P <schamb4@entergy.com>
Subject:
RE: BLIND REPORT Hi Dennis, I did speak with our lab manager, Tim Murphy. He said the issue was resolved by using a different blank urine matrix.
Denise Forsyth Office Manager EISohly laboratories, Incorporated (Ell) 5 Industrial Park Drive Oxford, MS 38655 Phone: (662) 236-2609 Fax: (662) 234-0253 www.elsohly.com
